SHS_430206 MEHV CBAY 14143

Radium-223 alpha Emitter Agent in Non-Intervention Safety Study in mCRPC popUlation for long-teRm Evaluation

Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing second primary cancers.

Inclusion Criteria:
Treatment decision to Radium-223 needs to be made independent from and before patient enrollment in the study. Histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases Signed informed consent.

Exclusion Criteria:
Previously treated with Radium-223 for any reason. Currently treated in clinical trials including other Radium-223 studies. Planned for the systemic concomitant use of other radiopharmaceuticals for treatment of prostate cancer or for other use.
Phase IV
NCT02141438
Cancer
Brain
Vivek Mehta, M.D.
Bayer
Maggie Klee
  • Swedish Medical Center